first-in-class RAS(ON) G12D inhibitor in #NSCLC at #AACR26. Zoldonrasib (RMC-9805) targets ACTIVE GTP-bound state of KRAS G12D · CBA Frontier Insights

Back to meeting Original

Back to meeting

Paul H, PharmD, RPH· @phsiao4 · X·2026-04-20 07:35· 2026-04-20Score60

Reading

KRAS / RAS targeting: from platform to Phase 3

zoldonrasib and VS-7375 in G12D remain Phase 1 — strong numbers, small samples, not head-to-head.

Body

first-in-class RAS(ON) G12D inhibitor in #NSCLC at #AACR26. Zoldonrasib (RMC-9805) targets ACTIVE GTP-bound state of KRAS G12D

Heat 3 · 2 likes · 0 replies · 1 repost

Source: Paul H, PharmD, RPH · x.com